FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2300955980> ?p ?o ?g. }

• W2300955980 endingPage "e3060" @default.
• W2300955980 startingPage "e3060" @default.
• W2300955980 abstract "To establish the comparative effectiveness of all available biologic therapy regimens for ankylosing spondylitis, we performed a systematic review and a Bayesian network meta-analysis of randomized controlled trials. PubMed, Medline, Embase, Cochrane library, and ClinicalTrials.gov were searched from the inception of each database to June 2015. Systematic review and network meta-analysis was reported according to the Preferred Reporting Items of Systematic Reviews and Meta-Analyses Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses. The primary outcome was 20% improvement of Assessments in SpondyloArthritis International Society Response Criteria (ASAS20) at Week 12 or 14; secondary outcomes were ASAS40, ASAS5/6, ASAS partial remission and 50% improvement in baseline Bath ankylosing spondylitis (AS) disease activity index. We reported relative risks and 95% confidence intervals from direct meta-analysis and 95% credible intervals from Bayesian network meta-analysis, and ranked the treatment for outcomes. We also used Grading of Recommendations Assessment, Development and Evaluation criteria to appraise quality of evidence. Fourteen RCTs comprising 2672 active AS patients were included in the network meta-analysis. Most biologic therapy regimens were more effective than placebo regarding all the outcomes assessed, except for secukinumab and tocilizumab. No differences between biologic therapies in the treatment of AS could be found, except for the finding that infliximab 5 mg was superior to tocilizumab. Infliximab 5 mg/kg had the highest probability of being ranked the best for achieving ASAS20, whereas notably, secukinumab had the highest probability of being ranked the second best. Our study suggests that no differences between biologic therapies in the treatment of AS could be found except that infliximab 5 mg was superior to tocilizumab. Infliximab 5 mg/kg seems to be the better biologic therapy regimen for AS. Secukinumab appears promising, though additional data is warranted. Nevertheless, these interpretations should be accepted very cautiously." @default.
• W2300955980 created "2016-06-24" @default.
• W2300955980 creator A5007791420 @default.
• W2300955980 creator A5035928125 @default.
• W2300955980 creator A5053533157 @default.
• W2300955980 creator A5056248574 @default.
• W2300955980 creator A5069255958 @default.
• W2300955980 date "2016-03-01" @default.
• W2300955980 modified "2023-09-25" @default.
• W2300955980 title "Comparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis" @default.
• W2300955980 cites W1617328014 @default.
• W2300955980 cites W1827932553 @default.
• W2300955980 cites W1866142084 @default.
• W2300955980 cites W1966756689 @default.
• W2300955980 cites W1971895240 @default.
• W2300955980 cites W1975137544 @default.
• W2300955980 cites W1979566788 @default.
• W2300955980 cites W1981680557 @default.
• W2300955980 cites W1990305566 @default.
• W2300955980 cites W2004646141 @default.
• W2300955980 cites W2009326492 @default.
• W2300955980 cites W2013163650 @default.
• W2300955980 cites W2042369988 @default.
• W2300955980 cites W2052129464 @default.
• W2300955980 cites W2063412360 @default.
• W2300955980 cites W2079180717 @default.
• W2300955980 cites W2081388746 @default.
• W2300955980 cites W2090132603 @default.
• W2300955980 cites W2092773063 @default.
• W2300955980 cites W2093043874 @default.
• W2300955980 cites W2102994864 @default.
• W2300955980 cites W2104675861 @default.
• W2300955980 cites W2106805511 @default.
• W2300955980 cites W2107021177 @default.
• W2300955980 cites W2107909189 @default.
• W2300955980 cites W2108984264 @default.
• W2300955980 cites W2108986329 @default.
• W2300955980 cites W2109346853 @default.
• W2300955980 cites W2109391487 @default.
• W2300955980 cites W2116351124 @default.
• W2300955980 cites W2116956799 @default.
• W2300955980 cites W2118706017 @default.
• W2300955980 cites W2118943683 @default.
• W2300955980 cites W2127609546 @default.
• W2300955980 cites W2134280423 @default.
• W2300955980 cites W2135400982 @default.
• W2300955980 cites W2137101132 @default.
• W2300955980 cites W2138055093 @default.
• W2300955980 cites W2139330551 @default.
• W2300955980 cites W2139525798 @default.
• W2300955980 cites W2139541503 @default.
• W2300955980 cites W2143387919 @default.
• W2300955980 cites W2143498069 @default.
• W2300955980 cites W2144625636 @default.
• W2300955980 cites W2158998079 @default.
• W2300955980 cites W2168708028 @default.
• W2300955980 cites W2193886619 @default.
• W2300955980 cites W2588681363 @default.
• W2300955980 cites W2916841405 @default.
• W2300955980 cites W4210974969 @default.
• W2300955980 cites W4248269869 @default.
• W2300955980 doi "https://doi.org/10.1097/md.0000000000003060" @default.
• W2300955980 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4839911" @default.
• W2300955980 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26986130" @default.
• W2300955980 hasPublicationYear "2016" @default.
• W2300955980 type Work @default.
• W2300955980 sameAs 2300955980 @default.
• W2300955980 citedByCount "25" @default.
• W2300955980 countsByYear W23009559802016 @default.
• W2300955980 countsByYear W23009559802017 @default.
• W2300955980 countsByYear W23009559802018 @default.
• W2300955980 countsByYear W23009559802019 @default.
• W2300955980 countsByYear W23009559802020 @default.
• W2300955980 countsByYear W23009559802021 @default.
• W2300955980 countsByYear W23009559802022 @default.
• W2300955980 countsByYear W23009559802023 @default.
• W2300955980 crossrefType "journal-article" @default.
• W2300955980 hasAuthorship W2300955980A5007791420 @default.
• W2300955980 hasAuthorship W2300955980A5035928125 @default.
• W2300955980 hasAuthorship W2300955980A5053533157 @default.
• W2300955980 hasAuthorship W2300955980A5056248574 @default.
• W2300955980 hasAuthorship W2300955980A5069255958 @default.
• W2300955980 hasBestOaLocation W23009559801 @default.
• W2300955980 hasConcept C126322002 @default.
• W2300955980 hasConcept C142724271 @default.
• W2300955980 hasConcept C168563851 @default.
• W2300955980 hasConcept C17744445 @default.
• W2300955980 hasConcept C1862650 @default.
• W2300955980 hasConcept C189708586 @default.
• W2300955980 hasConcept C199539241 @default.
• W2300955980 hasConcept C204787440 @default.
• W2300955980 hasConcept C27081682 @default.
• W2300955980 hasConcept C2776260265 @default.
• W2300955980 hasConcept C2776478404 @default.
• W2300955980 hasConcept C2777138892 @default.
• W2300955980 hasConcept C2777178219 @default.
• W2300955980 hasConcept C2777402515 @default.
• W2300955980 hasConcept C2777575956 @default.

• next